Preventing, Monitoring, and Managing Ototoxicity Related to Cisplatin: Proactive Rather Than Reactive Approaches Are Needed.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Improving the usability of grading scales for drug-induced ototoxicity with a focus on real world data collection.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025
   Article
2. Outcomes of Window Therapy with Carboplatin and Ifosfamide for Pediatric Osteosarcoma: A Case Series.Children (Basel, Switzerland) · 2023
   Article
3. Roadmap to a Global Template for Implementation of Ototoxicity Management for Cancer Treatment.Ear and hearing
   Review

Corrections and comments

• Comment on
  Cisplatin-Induced Ototoxicity: A Concise Review of the Burden, Prevention, and Interception Strategies.2023

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as